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Abstract: The administration of immune checkpoint inhibitors (ICIs) often leads to immune-related
adverse events. However, their effect on auditory function is largely unexplored. Thorough preclinical
studies have not been published yet, only sporadic cases and pharmacovigilance reports suggest
their significance. Here we investigated the effect of anti-PD-1 antibody treatment (4 weeks,
intraperitoneally, 200 µg/mouse, 3 times/week) on hearing function and cochlear morphology in
C57BL/6J mice. ICI treatment did not influence the hearing thresholds in click or tone burst stimuli
at 4–32 kHz frequencies measured by auditory brainstem response. The number and morphology
of spiral ganglion neurons were unaltered in all cochlear turns. The apical-middle turns (<32 kHz)
showed preservation of the inner and outer hair cells (OHCs), whilst ICI treatment mitigated the
age-related loss of OHCs in the basal turn (>32 kHz). The number of Iba1-positive macrophages
has also increased moderately in this high frequency region. We conclude that a 4-week long ICI
treatment does not affect functional and morphological integrity of the inner ear in the most relevant
hearing range (4–32 kHz; apical-middle turns), but a noticeable preservation of OHCs and an increase
in macrophage activity appeared in the >32 kHz basal part of the cochlea.
Keywords: immune checkpoint inhibitor; anti-PD-1 antibody; hearing loss; immune-related adverse
events (irAE); auditory brainstem response (ABR); cochleogram; spiral ganglion neuron; Iba1;
hair cells; macrophage
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1. Introduction
Activation of cellular immunity and abolishment of self-tolerance against tumor cells in the host
organism (a.k.a., immune checkpoint inhibition, ICI) is an efficient and preferred way of antitumor
pharmacotherapy with growing clinical applications and expanding therapeutic indications.
According to the cancer immunoediting hypothesis, one of the mechanisms tumor cells use
to escape from immunosurveillance is to establish an immunosuppressive microenvironment by
production of adenosine [1] or expressing programmed death-ligand 1 (PD-L1), a negative costimulatory
molecule of the B7-CD28 superfamily. Binding of their PD-L1 to the programmed cell death protein 1
(PD-1) receptors on T-cells results in the inhibition of T-cell proliferation and cytokine production with
the consequent evasion of immunosurveillance [2,3]. Inhibitors of the PD-1 receptor (like monoclonal
antibodies such as pembrolizumab or nivolumab) are one option amongst the immunotherapeutic
agents called checkpoint inhibitors that prevent the activation of these negative costimulatory pathways
and thus restore the host’s anti-tumor immunity [4–6]. Numerous tumors, including advanced
metastatic melanoma, colorectal cancer, non-small-cell lung cancer (NSCLC), and renal cell carcinoma
(RCC), show promising responses to anti-PD-1 monoclonal antibody treatment [4,5,7,8].
However, activation of the immune system often causes atypical side effects, called immune-related
adverse events (irAE). The immunological imbalance may lead to uncontrolled immune responses and
breakdown of the peripheral tolerance, resulting in autoimmune-like symptoms. The most common
irAEs involve gastrointestinal, dermatologic, hepatic, and endocrine toxicities. Less frequently,
symptoms affecting the lung, eye, kidney, pancreas, the nervous, and the hematopoietic system are
reported, as well [4,7,9–11].
Publications on cases of audiovestibular adverse events are much more sporadic [12–14] and no
clinical studies have evaluated the impact of PD-1 inhibitors on the audiovestibular system so far.
Taking into consideration that high-frequency hearing loss is not always recognized by the patient and
vertigo can be attributed to the general symptoms caused by the tumor, a significant number of cases
with audiovestibular side effects might stay unrevealed.
In recent years it has become clear that the inner ear is not an immune privileged organ [15,16].
It contains bone-marrow-derived resident macrophages [17–20], and insults of the inner ear induces
the invasion of the cochlea by monocytes and T cells [20,21]. The released proinflammatory
cytokines, chemokines, or reactive oxygen species, by the activated immune cells evoke further
cellular infiltration [19,22,23]. This cochlear immune system can be involved in either the injury repair
processes or the pathogenesis of sensorineural hearing losses [15,16]. Therefore, raising the question of
irAEs after the administration of ICIs is well substantiated.
Our aim was to investigate the alterations, if any, caused by PD-1 inhibitor monoclonal antibody
treatment in the hearing function and cochlear morphology. To this end, we used a murine model and
connected the functional auditory brainstem response (ABR) measurements with histopathological
examinations: Cochlear whole-mount dissections to evaluate hair cell numbers, hematoxylin/eosin
(HE) staining on mid-modiolar sections to detect changes in spiral ganglion neuron (SGN) numbers and
structure, and Iba1 immunohistochemistry to compare the number of activated cochlear macrophages
between the treated and control group. We found a preserved function and morphology in the most
relevant hearing range (4–32 kHz) and in the corresponding apical-middle cochlear turns, and an
enhanced outer hair cell (OHC) survival in the high-frequency basal turn with a moderate increase in
the number of Iba1-positive macrophages.
2. Results
2.1. Differences in Hearing Thresholds between Treatment Groups Could Not Be Observed after PD-1 Inhibition
To investigate whether anti-PD-1 antibody therapy has an effect on the function of hearing, hearing
thresholds of isotype control, anti-PD-1 antibody-treated mice were determined and compared at the
end of the treatment period. There were no statistically significant differences either by broadband
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click or frequency-specific pure tones at frequencies 4–32 kHz (Figure 1). Both groups showed hearing
performance characteristic for this age of C57BL/6J mice [24].
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Cochleograms, plotted with the evaluation of the staining of actin filaments in inner and outer 
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(DAPI), showed that there is no hair cell loss in the ≤32 kHz frequency range in either treatment 
groups. However, anti-PD-1 antibody treatment mitigated the loss of OHCs at frequencies higher 
than 32 kHz (Figure 2A,B,E,F). Inner hair cell (IHCs) loss was undetectable in the basal turn, as well, 
in both treated groups. Statistical analysis, based on hair cell densities in the apical/middle/basal 
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Figure 1. Hearing thresholds of C57BL/6J mice ere not influenced by anti-PD-1 antibody treatment.
Auditory brainstem response (ABR) measurements were carried out at the end of the 4-week long
treatment period (see flowchart in Figure 1 for details). No difference in hearing thresholds was detected
either in click or in tone burst stimuli in the 4–32 kHz frequency range between the anti-PD-1 antibody
(n = 9) and the control group (n = 10). Data represent mean ± SEM. Two-way ANOVA followed by
Bonferroni post-hoc test; p < 0.05 was considered statistically significant (see Section 4).
2.2. Anti-PD-1 Antibody Treatment Did Not Affect the Number of Hair Cells in the Apical and Middle Cochlear
Turns, but Preserved OHCs in the Basal Turn
Cochleograms, plotted with the evaluation of the staining of actin filaments in inner and outer
HCs by Alexa Fluor 594 Phalloidin and counterstaining of nuclei with 4′,6-diamidino-2-phenylindole
(DAPI), showed that there is no hair cell loss in the ≤32 kHz frequency range in either treatment groups.
However, anti-PD-1 antibody treatm nt mitigated the lo s of OHCs at frequencies higher than 32 kHz
(Figure 2A,B,E,F). Inner hair cell (IHCs) los was undetectable in the basal turn, s well, in both treated
groups. Statistical analysis, based on hair cell densities in the apical/middle/basal subdivisions of the
tonotopic axis of the cochleae, proved that the difference in OHC density between the control and the
anti-PD-1 antibody-treated groups is significant (Figure 2C,D).
2.3. Number of SGNs Was Not Changed by Anti-PD-1 Antibody Treatment in Either Cochlear Turn
There was no alteration in SGN number and morphology after anti-PD-1 antibody treatment in
either the apical, middle, or the basal cochlear turns on HE staining of cochlear sections (Figure 3).
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Figure 2. Anti-PD-1 antibody treatment did not change the number of hair cells in the apical and middle
turns, but mitigated the loss of outer hair cells (OHCs) in the basal cochlear turns in C57BL/6J mice.
Cytocochleograms of the control (A) and the anti-PD-1 antibody treated (B) group (n = 6–6) show the
lack of inner hair cell (IHC) and O loss in the whole length of the cochlear duct and in the <32 kHz
rang , respectively. The loss of OHC in the high-fr quency basal turn was less prominent in the
anti-PD-1 antibody-treated g oup. Bar graphs of inner (C) and outer (D) hair cell densities in he three
cochlear segments demonstrate the significant difference in OHC in the basal turn. (E,F) Representative
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images of whole-mount dissections of the organ of Corti stained with Alexa Fluor 594 Phalloidin
(red) and 4′,6-diamidino-2-phenylindole (DAPI) (blue). Distance from apex was correlated with
hearing frequency by using the frequency–place equation by Müller et al., (2004). IHC, inner hair cell,
OHC1/2/3: First, second, and third rows of outer hair cells. The scale bar indicates the magnification.
Data represents mean ± SEM. Two-way ANOVA followed by Bonferroni post-hoc test; * p < 0.05 was
considered statistically significant (see Section 4).
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in the apical (a), middle (m), and basal (b) turns. (B) Statistical analysis has shown no significant 
Figure 3. Hematoxylin/eosin (HE) staining of the spiral ganglia. (A) Representative image of a
HE-stained mid-mod olar ection of a cochlea with a 6.3× objective. The squares ndicate the spiral
ganglia in the apical ( ), middle (m), and b sal (b) turns. (B) Statistical analysis has shown no significant
difference between the spiral ganglion neuron (SGN) numbers in the control nd anti-PD-1 antibody
treated animals (n = 4–4 mice, 5 sections each). (C) Representative images of the spiral ganglia in the
apical, middle, and basal turns demonstrate the lack of difference in SGN numbers and morphology
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between the control and anti-PD-1 antibody treatment groups (40× objective). The scale bar indicates
the magnification. Data represents mean ± SEM. Two-way ANOVA followed by Bonferroni post-hoc
test; p < 0.05 was considered statistically significant (see Section 4).
2.4. PD-1 Inhibition Did Not Affect the Number of Iba-1 Positive Macrophages in the Apical and Middle
Cochlear Turns, but Increased It in the Basal Turn
Iba1-positive macrophages were detected mainly in the Rosenthal’s canal, along the peripheral
processes of the SGNs, in the stria vascularis and the spiral ligament as presented in Figure 4.
The number of Iba1-stained cells was similar in the control and anti-PD-1 antibody-treated group in
the apical and middle cochlear turns (ratio of the cell number in treated/control group were 1.05 and
0.96, respectively). However, in the basal turns, the number of Iba1-positive cells was 1.56 times higher
in the anti-PD-1 antibody-treated group (Figure 4).
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he acrophage-specific Iba1 staining shows a moderately higher intensity 3,3′-diaminobenzidine DAB
staining (i.e., higher macrophage signal) in the anti-PD-1 antibody-treated than in the control animals
(representative sections from control (A) and anti-PD-1 antibody-treated (B) animals). The number of
Iba1-positive cells was 1.56 times higher in the basal cochlear turn of the ICI-treated mice (control, n
= 2; anti-PD-1 antibody-treated, n = 3). Roman numerals indicate enlarged areas of the Rosenthal’s
canal (I), the peripheral processes of the SGNs (II), the stria vascularis (III), and the spiral ligament (IV).
The details of the staining procedure are described in the Section 4.
3. Discussion
The role of the immune system in hearing and hearing losses is in the focus of auditory
research [19,25,26]. Presence of immune cells (e.g., resident macrophages, infiltrating monocytes) [25,27,28]
and their activation contributes fundamentally to the maintenance of cochlear homeostasis and
function [21,26,28–32]. However, overactivation of the immune responses can cause cochlear tissue
damage and hearing impairment. Certain medications used in clinical practice (e.g., platinum antitumor
compounds or aminoglycoside antibiotics)—similarly to cochlear aging and noise exposure—triggers
inflammation [16,23,33–40] that results in the development of drug-induced hearing loss [34,41–43].
As a consequence, the immunostimulatory PD-1 inhibitors may potentially have harmful effects on
hearing as it has been reported in some case studies [12–14].
In our mouse model the 4-week long mouse-specific anti-PD-1 therapy did not affect the function
of hearing in the 4–32 kHz frequency range and the number of IHCs and OHCs in the apical-middle
cochlear turns (<32 kHz). This is in accordance with a murine study by Spielbauer et al. who found
that the PD-1 inhibitor monotherapy had no impact on hearing thresholds between 8–40 kHz and
on hair cell numbers in the range of 8–32 kHz. However, the Spielbauer study did not investigate
the effect of PD-1 inhibition on SGNs and cochlear immune response (e.g., macrophage activation),
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on the numbers of hair cells in the high frequency regions (>32 kHz) and did not use isotype antibody
for control [44]. Kuzucu et al. has found slight and temporary elevation in hearing threshold after
anti-PD-1 treatment [45]. Their observation of moderate loss of OHCs was not based on quantitative
data or standard methods like cochleogram plotting [46–48], and the tonotopy was disregarded as well.
On the other hand, these ABR results are in contrast with the observations of three case reports,
where sudden bilateral hearing loss was detected at high frequencies following PD-1 inhibitor
treatment [12–14]. Furthermore, there are 14 reported cases of sudden hearing loss suspected to
result from the use of PD-1 inhibitors in the FDA Adverse Event Reporting System Public Dashboard.
Fifty serious and 6 non-serious ear and labyrinth disorders are reported in connection with Keytruda
(pembrolizumab) in the EudraVigilance database of the European Medicines Agency. However,
these reports do not establish factual causation between the treatment and the symptoms. Clinical
studies evaluating the impact of PD-1 inhibitors on the audiovestibular system have not been
performed yet.
Immune activation in the cochlea may also be associated with SGN injury [49,50]. The lacking
effect of anti-PD-1 therapy on the SGN number and morphology along the tonotopic axis of the cochlear
duct in our experiments corresponds well with our measurement on the hearing function. According
to our best knowledge, there are no data on the effect of immune checkpoint inhibitor therapy on SGNs
we could compare to.
The C57BL/6J strain shows age-related hearing impairment with an increase in hearing thresholds
and OHC loss expanding from basal part of the cochlea toward the apical region [51,52]. Loss of
IHCs occurs later and progresses much more slowly [52]. In our experiments, whilst IHC loss was
negligible along the whole cochlear duct, the age-related loss of OHCs in the basal turn was alleviated
by anti-PD-1 administration, suggesting a moderate protection of age-related OHC loss at the high
frequency part of the tonotopic axis. We have not found data in the literature on the effect of immune
checkpoint inhibitors on hair cells in the >32 kHz frequency range, i.e., in the basal cochlear turn either.
This preservation did not appear in our ABR results, because those measurements were not performed
above 32 kHz due to the elevated baseline thresholds of C57BL/6 mice at high frequencies [53,54].
The observed OHC preservation in the high frequency range of the cochleogram (>32 kHz) was
accompanied with the increased number of Iba-1-positive macrophages exclusively in the basal cochlear
turn after anti-PD-1 treatment. According to the literature, macrophages from different cochlear turns
show different phenotypes and response patterns to hair cell degeneration in age-related hearing
loss (AHL) [27] and only the basal macrophages displayed marked activation of antigen-presenting
function for acoustic trauma [20].
The enhanced macrophage activity may be responsible for the mitigated OHC loss in the
basal turn with mechanisms similar to those that reduced pathology and improved memory in the
Alzheimer’s disease (AD) murine model after a PD-1 immune checkpoint blockade. AHL is partly
contributed to chronic, low-grade inflammation in the cochlea, consisting of failure in downregulation
of proinflammatory proteins and accumulation of cell debris resulting from insufficient elimination. In
AD, amyloid-β (Aβ) accumulation leads to a chronic stimulation of the immune system which initiates
a vicious circle: Cytokines such as interleukin 1-β, IL-6, and tumor necrosis factor-α stimulate the
synthesis of β-amyloid precursor protein and Aβ peptides [55]. The blockade of the PD-1 pathway
results in an increased systemic IFN-γ-dependent immune response that facilitates the entry of
monocyte-derived macrophages to the brain, thus enhancing the elimination of Aβ plaques [56–58].
We assume that our findings of mitigated outer hair cell loss in the basal cochlear turn following ICI
treatment and a simultaneous increased macrophage Iba1-immunoreactivity in the corresponding
region can be a consequence of a similar mechanism: Stimulated immune response might help cleaning
accumulated cell debris, thus limiting chronic inflammation which results in more preserved cellular
integrity of the organ of Corti.
Despite the fact that overactivation of the immune system is involved in the pathology of
sensorineural hearing losses, the revolutionary anti-PD-1 therapy with an immunostimulatory effect
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does not seem to have a significant impact on the functional and morphological integrity of the inner
ear in the most relevant hearing range. The immune blockade of PD-1 does not lead to hearing loss or
worsening of the pre-existing hearing impairment in the apical-middle turns (<32 kHz). Moreover, a
noticeable preservation of OHCs appears in the high frequency (>32 kHz) basal part of the cochlea.
Our findings also demonstrate the Janus face of immuno-pharmacotherapy.
4. Materials and Methods
4.1. Experimental Animals
Experimental procedures were carried out on male C57BL/6J mice (Oncological Research Center,
Department of Experimental Pharmacology, H-1122 Budapest, Hungary), ranging from 8 to 10 weeks
of age at the beginning of the study. Mice were maintained under a 12:12 h light–dark cycle under
controlled environmental conditions (20–24 ◦C and 35–75% relative humidity) in individually ventilated
cages with shelters, holding 2–3 animals per cage. Standard rodent chow and tap water were provided
ad libitum throughout the entire duration of the experiment. All procedures were approved by the
National Scientific Ethical Committee on Animal Experimentation and the Semmelweis University’s
Institutional Animal Care and Use Committee (H-1089 Budapest, Hungary) in accordance with NIH
guidelines (National Research Council (2011), Guide for the Care and Use of Laboratory Animals:
Eighth Edition) and permitted by the government of Food Chain Safety and Animal Health Directorate
of the Government Office for Pest County (project identification code: PE/EA/1912-7/2017; date of
approval: November 2017).
4.2. Experimental Groups and Drug Administration
Twenty C57BL/6J mice were randomly assigned to either a control (n = 10) or an anti-PD-1
antibody-treated group (n = 9, one animal died during the experiment). Purified InVivoMAb
rat IgG2a isotype control antibody (clone 2A3), and in addition, InVivoMAb anti-mouse PD-1
antibody (clone RMP1-14), used for immune checkpoint blockade were purchased from BioXCell.
Drugs were administered once on the day of treatments by intraperitoneal (i.p.) injections at a dose of
200 µg/mouse/treatment. Antibodies were delivered to mice three times per week over the treatment
period lasting for 4 weeks (Figure 5). Treatment schedule was based on previous publications assessing
the anti-tumor efficacy and side-effect profile of this particular antibody clone [59–62].
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assessing the anti-tumor efficacy and side-effect profile of this particular antibody clone [59–62]. 
 
Figure 5. Flowchart of the experiments. C57BL/6J mice received either an anti-mouse PD-1 (anti-PD-
1 antibody) or an IgG2a isotype antibody (control) injection intraperitoneally three days per week for 
4 weeks with a 2–3 days lag time between treatments. Syringes indicate the application of antibodies 
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Figure 5. Flo chart of the experi ents. C57BL/6J ice received either an anti- ouse PD-1 (anti-PD-1
antibody) or an IgG2a isotype antibody (control) injection intraperitoneally three days per week for 4
weeks with a 2–3 days lag time between treatments. Syringes indicate the application of antibodies at
the dose of 200 µg/mouse/treatment. Measuring the function of hearing by auditory evoked potentials
(ABR) and harvesting of cochlear tissues for morphological analysis were performed at the end of the
treatment period.
4.3. Hearing Assessment
ABR audiometry was performed at the end of the treatment period to test auditory function by
measuring hearing thresholds at different frequencies [63]. Briefly, evoked potentials were recorded in
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the right ear of each mouse under ketamine/xylazine anesthesia (100 and 10 mg/kg, i.p., respectively).
Body temperature of mice was maintained at 36–38 ◦C with a temperature-controlled heating pad
(Supertech Instruments, H-7624 Pécs, Hungary). ABR waves were recorded with subdermal needle
electrodes placed at the vertex (active electrode), behind the right pinna (reference electrode), and at the
rear leg (ground). Measurements were carried out in a sound-proof chamber using a TDT workstation
(TDT system 3 with RX6 signal processor and RA16 Medusa Base Station; Tucker–Davis Technologies
(TDT), Alachua, FL, USA). Click (0.4 ms duration) and tone burst (3 ms duration, 0.2 ms rise/decay,
frequency range 4–32 kHz) stimuli were generated in the SigGenRP software package and delivered
in a closed acoustic system using EC-1 electrostatic speaker, controlled by the BioSigRP software.
Digital signals were amplified by RA4PA Medusa PreAmplifier connected to RA4LI Low Impedance
Headstage (TDT, Alachua, FL, USA). Sound pressure levels of the click stimulus were increased in
10-dB steps from 0 to 80 dB, whilst intensity was attenuated in 10 dB steps from 90 to 10 dB in tone
burst stimulation mode controlled by a PA5 Programmable Attenuator (TDT, Alachua, FL, USA).
For calibrating the sound delivery system, a half-inch free field preamplifier integrated microphone
was used (ACO Pacific Inc., Belmont, CA 94002, USA; Model 7017) with the application of the SigCalRP
calibration software. Evoked potentials were amplified, filtered, and averaged 800 times in real-time.
The hearing threshold was defined as the minimal intensity level at which an ABR waveform with an
identifiable peak could be detected visually.
4.4. Tissue Preparation
The 10 control and 9 anti-PD-1 antibody-treated mice were euthanized, and both right and left
inner ears were dissected from the temporal bone. After removing the stapes and carefully performing
two openings on the cochleae—one in the apex and one in the round window—they were perfused
with 0.2 mL 4% paraformaldehyde (PFA) in phosphate-buffered saline (PBS; pH = 7.4), then immersed
in the 4% PFA for 2 h at room temperature in Eppendorf tubes on a rocking shaker. Cochleae were
then decalcified in 5% EDTA in PBS with 0.4% PFA in 15-mL centrifuge tubes for 6 days at room
temperature on a rocking shaker. The EDTA solution over the cochleae was changed daily.
4.5. Whole-Mount Cochlear Dissection and Phalloidin/DAPI Staining
The organ of Corti was removed from the decalcified right cochleae of 6 control and 6 anti-PD-1
antibody-treated animals under stereomicroscope using microsurgical instruments. The bony wall, the
vestibular system, spiral ligament, modiolus, and tectorial membrane were carefully removed, and the
basilar membrane was cut into 3–6 longitudinal segments. The samples were rinsed three times in
PBS for 5 min each time, then immersed in 0.3% Triton X-100 in PBS for 10 min and incubated with
Alexa Fluor 594 Phalloidin (1:200, Thermo Fisher Scientific, Waltham, MA, USA) for 40 min at room
temperature. After washing 3 times with PBS for 5 min, nuclei were stained with DAPI (1 µmol/L,
5 min, Cell Signaling Technology, Leiden, The Netherlands). Subsequently, samples were washed
3 times in PBS for 5 min. Finally, cochlear turns were placed on a glass slide using Prolong Gold
antifade reagent (Thermo Fisher Scientific, Waltham, MA, USA).
4.6. Cytocochleogram Plotting
Hair cells were imaged in the epifluorescent mode of a Leica LMD6 microscope coupled to a
CCD camera (DFC7000T; Leica Biosystems, Wetzlar, Germany) using a 40×HC PL Fluotar objective
(Leica Biosystems, Wetzlar, Germany). Cells were counted manually. In every 190–250 µm segment
alongside the pillar cells the number of missing hair cells was counted. Hair cell counts were analyzed
using a customized version of the Kresge Hearing Research Institute CytoGram Program, Version 3.0.6
(Ann Arbor, MI, USA). An average of 95% of the total length of the basilar membrane from the apex
was evaluated. In both the control (n = 6) and anti-PD-1-treated groups (n = 6), cochleograms were
plotted. The frequency-place equation by Müller et al. (2004) was used to correlate the location to
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frequency. For statistical analysis, the evaluated section of the basilar membrane was divided into
three equal segments in length: apical, middle, and basal.
4.7. Modiolar Sectioning for Hematoxylin-Eosin Staining and Immunohistochemistry
A graded series of ethanol solutions (35, 50, 70%, 2 × 15 min each) was used to dehydrate the
decalcified tissues. Further dehydration with a graded series of ethanol (70, 80, 95% and absolute
ethanol, each of them 2 × 1 h) and xylol treatment (2 × 1 h) were performed in a Leica TP 1020 tissue
processor (Leica Biosystems, Wetzlar, Germany). Ultimately, the cochleae were embedded in 60 ◦C
paraffin, and 4-µm sections were cut with a Leica HistoCore MULTICUT microtome (Leica Biosystems,
Wetzlar, Germany) for hematoxylin/eosin (HE) and Iba1 staining.
4.8. Hematoxylin/Eosin (HE) Staining and Counting Spiral Ganglion Neurons (SGNs)
To avoid repeated counting of the same SGNs, every fourth section was stained with HE (Harris
Hematoxylin: Sigma–Aldrich, St. Louis, MO, USA; Eosin: Leica Biosystems, Wetzlar, Germany).
Images of the Rosenthal’s canal were acquired in the brightfield mode of a Leica LMD6 microscope
(Leica Microsystems, Wetzlar, Germany) using a 40× HC PL Fluotar objective (Leica Microsystems,
Wetzlar, Germany). SGNs were counted in a representative area (16,785 µm2 in average, but min.
6000 µm2) in four anti-PD-1-treated (2 left and 2 right ears) and four control (2 left and 2 right ears)
animals. Five sections per mouse were evaluated and the average density of SGNs was calculated in
the apical, middle, and basal turns.
4.9. Iba1 Immunohistochemistry
The 4-µm modiolar sections were deparaffinized and hydrated with xylene and a graded series of
ethanol solutions, respectively. Heat-induced antigen retrieval was performed in microwave-heated
citrate buffer (pH ≈ 6.5) for a total time of 10 min (4 times 1.5 min and 2 times 2 min, with pauses of the
same length in between). The slides were cooled, washed in PBS for 3 × 5 min, then the endogenous
peroxidase activity was blocked with 3% H2O2 in PBS for 10 min. Samples were washed in PBS
for 3 × 5 min, blocked in 2.5% normal goat serum (Vector Laboratories, Inc., Burlingame, CA 94010,
USA) containing 2.5% non-fat dried milk powder in PBS for 1 h at room temperature, then incubated
with the primary antibody (anti-Iba1, 1:2000, Rabbit, FUJIFILM Wako Pure Chemical Corporation,
Neuss, Germany) overnight at 4 ◦C. After washing 3 times for 10 min in PBS, secondary antibody
was used SignalStain® Boost IHC Detection Reagent (HRP, Rabbit; Cell Signaling Technology, Leiden,
The Netherlands) in accordance with the manufacturer’s instructions, and washed again. The specific
signal was developed with ImmPACT DAB EqV Substrate Kit (Vector Laboratories, Inc., Burlingame,
CA 94010, USA), dehydrated, and covered by coverslips using CV Mount (Leica Biosystems, Wetzlar,
Germany). Iba1 positive cells were evaluated in an observer-blinded fashion by two independent
persons in 6 control (from 2 animals) and 6 anti-PD-1 antibody-treated (from 3 animals) 4-µm sections.
4.10. Statistics
Data were analyzed with two-way ANOVA followed by a Bonferroni post-hoc comparison test
using the 8.4.3 version of GraphPad Prism. Results are indicated as mean ± standard error of the
mean (SEM).
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